Impacts of the Build Back Better Act on the Healthcare Industry

With the Build Back Better Act inching through the legislature, uncertainty is building regarding its effects on the healthcare industry. In Stat News’ D.C. Diagnosis newsletter, Nicholas Florko discusses how the included pricing caps will affect insulin manufacturers and other drug makers. In addition, he covers the Biden administration’s push for antiviral medication and comments on drug pricing from moderate Democrat, Senator Krysten Sinema (D-Arizona).

The newsletter shares this in regards to annual drug price hikes, “Craig Garthwaite, a professor at Northwestern University, told STAT it won’t make rational sense for drug makers to hike their prices more than inflation if the Democrats’ bill passes, because of the provision that would force them to repay taxpayers all the profits they receive from raising their prices more than inflation.”

Read more by clicking here.